Abstract
Jan Hontelez and colleagues argue that the cost-effectiveness studies of HIV treatment scale-up need to include health system constraints to be more informative.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Africa South of the Sahara
-
Anti-HIV Agents / therapeutic use*
-
Cost-Benefit Analysis*
-
HIV Infections / drug therapy*
-
HIV Infections / economics
-
Humans
-
Public Health / economics*
Grants and funding
JACH and TB are funded by UNAIDS through the project “Optimal Resource allocation and long-term financing in the HIV sector in the ESA region.” JACH also received funding through Netherlands Organization for Scientific Research (NWO) Talent Scheme Veni. RMPMB and EM are funded through the Netherlands Organization for Scientific Research (NWO) Talent Scheme Vici. GMR is funded by USAID South Africa, the HIV Modelling Consortium, and the World Health Organization. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.